Posted on the August 31, 2021 under Webinars
WEBINAR: Addressing Challenges of NGS Assay Validation with Precision NGS-focused Seraseq Oncology Controls
Oncology NGS assay validation using highly multiplexed reference samples that imbibe clinical patient profiles and characteristics, for solid tumors and heme malignancies.
Omo Clement, Director of Oncology Products, LGC SeraCare
Omo Clement is Director of Oncology Products, in the Clinical Diagnostics Division of LGC SeraCare. In this role, he is responsible for the division’s Oncology-related reference material portfolio. Prior to joining LGC-SeraCare in 2018, Dr. Clement managed diagnostic oncology products at various biotechnology companies such as Bio-Rad Laboratories, RainDance Technologies, Asuragen Inc., as well as HTG Molecular Diagnostics, Inc. Dr. Clement obtained a PhD in Chemistry at Queen’s University, Ontario, CANADA, and completed a post-doctoral research fellowship at the Environmental Molecular Sciences Laboratory (EMSL) of the Pacific Northwest National Laboratory (PNNL), Richland, WA, USA.
WHO SHOULD ATTEND?
- Clinical Lab Managers/Directors
- Molecular Pathology Lab
- Clinical Oncologists
- NGS OEMs
- Cancer Diagnostic Testing Labs
- Biomedical research institutes (Cancer Biology)
- Cancer treatment hospitals
WHAT YOU WILL LEARN:
The range of innovative and oncology reference controls and solutions for NGS assays analyzing pan-cancer disease profiling, treatment/disease monitoring and patient response to I-O therapies (immuno-oncology).